A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Required: * Antiretroviral therapy during study treatment only in patients with CD4 count \< 500 cells/mm3 (per 12/30/94 amendment). Allowed: * G-CSF for a second occurrence of grade 3 or 4 neutropenia (per 12/30/94 amendment). * Nonsteroidal anti-inflammatory agents including acetaminophen for drug-related fevers. * Systemic steroids for no more than 1 week in any 30-day period. * PCP prophylaxis with TMP/SMX, dapsone, or inhaled pentamidine, if patient has a history of PCP or a CD4 count \< 250 cells/mm3. Allowed only in patients with CD4 count \< 100 cells/mm3: * Maintenance doses of ganciclovir, pyrimethamine/sulfa and TMP/SMX for stable, well-controlled opportunistic infections. * Non-myelosuppressive treatment IND medications. Prior Medication: Required: PER AMENDMENT 11/20/95: * Stable dose of antiretroviral therapy required for at least 21 days prior to study entry for all patients. (Changed from - Stable dose of antiretroviral therapy for at least 21 days prior to study entry in patients with CD4 count \< 500 cells/mm3 (per 12/30/94 amendment). Patients must have: * AIDS-related Kaposi's sarcoma. * PER AMENDMENT 11/20/95: CD4 lymphocyte count \>= 100 but \< 500 cells/mm3. (Changed from - HIV infection.) * PER AMENDMENT 11/20/95: All Patients will receive antiretroviral therapy. (Changed from - Current antiretroviral therapy IF CD4 count \< 500 cells/mm3 (per 12/30/94 amendment).) * No active opportunistic infections requiring induction therapy. * Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Other active malignancies (except basal cell carcinoma of the skin and in situ cervical cancer). * Alteration in mental status that may prevent compliance. * Cardiac functional capacity of Class II or worse OR regional wall abnormalities or abnormal ejection fraction on two-dimensional echocardiogram, if performed. Concurrent Medication: Excluded: * Chemotherapy, interferons, or immune modulators for Kaposi's sarcoma. * Myelosuppressive agents such as induction doses of ganciclovir, Fansidar (pyrimethamine/sulfadoxine), or any other investigational drugs (with the exception of non-myelosuppressive treatment IND medications in specific patients). * GM-CSF or erythropoietin (except for a second grade 3/4 neutropenia or anemia). * G-CSF. Patients with the following prior conditions are excluded: * History of myocardial infarction or significant arrhythmias. * History of symptomatic hypoglycemia. Prior Medication: Excluded: * Systemic therapy (including chemotherapy, interferons, and immune modulators) for Kaposi's sarcoma within 4 weeks prior to study entry.